Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 9/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2486076 | 0.92 | CHRM1 (1.00) | CHRM1LMNATOP1 | |
| SCHEMBL2883197 | 0.91 | CHRM1 (0.80) | CHRM1LMNATOP1 | |
| SCHEMBL14413508 | 0.90 | CHRM1 (0.78) | CHRM1LMNAHTTTOP1 | |
| SCHEMBL2491457 | 0.88 | CHRM1 (0.83) | CHRM1LMNATOP1 | |
| SCHEMBL2881808 | 0.87 | CHRM1 (0.70) | CHRM1LMNAMAPTHTT | |
| SCHEMBL2877807 | 0.87 | CHRM1 (0.74) | CHRM1LMNAHTT | |
| SCHEMBL2877473 | 0.87 | CHRM1 (0.67) | CHRM1LMNA | |
| SCHEMBL16341817 | 0.86 | CHRM1 (1.00) | CHRM1LMNA | |
| SCHEMBL2881818 | 0.86 | CHRM1 (0.73) | CHRM1LMNA | |
| SCHEMBL2882158 | 0.85 | CHRM1 (0.68) | CHRM1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | claimed |
| US-20100317692-A1 | Quinolone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | claimed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | claimed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2007067489-A1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317692-A1 | Quinolone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, MTNR1A | CHRM1 1/4885LMNA 3503/4885MAPT 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.